Introduction to Novel P2y12

Sentence Examples

Discover more insights into Novel P2y12

Keywords frequently search together with Novel P2y12

Narrow sentence examples with built-in keyword filters

Novel P2y12 sentence examples within novel p2y12 receptor

novel p2y12 receptor

Therefore, the PD interaction liability of the novel P2Y12 receptor antagonist selatogrel with irreversible (i.

Insights from In Vitro and Clinical Data to Guide Transition from the Novel P2Y12 Antagonist Selatogrel to Clopidogrel, Prasugrel, and Ticagrelor.

novel p2y12 receptor

Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes.

Erratum to: CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure

More novel p2y12 receptor sentences More Sentences

Novel P2y12 sentence examples within novel p2y12 inhibitor

novel p2y12 inhibitor

This meta-analysis investigated whether ticagrelor, a novel P2Y12 inhibitor, was superior to clopidogrel and prasugrel in efficacy and safety for DM patients undergoing PCI.

Efficacy and Safety of Ticagrelor in Diabetes Patients Undergoing Percutaneous Coronary Intervention: A Meta-analysis of Randomized Controlled Trials.

novel p2y12 inhibitor

For over a decade novel P2Y12 inhibitors, which have increased specificity, potency and efficacy have been available, prompting studies which have tested whether these newer agents can be used in aspirin-free anti-platelet regimens to augment clinical benefits in patients post-PCI.

Aspirin-free antiplatelet regimens after PCI: insights from the GLOBAL LEADERS trial and beyond.

More novel p2y12 inhibitor sentences More Sentences

Novel P2y12 sentence examples within novel p2y12 antagonist

novel p2y12 antagonist

BACKGROUND AND PURPOSE: Ticagrelor is a novel P2Y12 antagonist, and little is known about its efficacy and safety in the endovascular treatment of aneurysms.

Ticagrelor versus Clopidogrel in the Dual Antiplatelet Regimen for Intracranial Stenting or Flow-Diverter Treatment for Unruptured Cerebral Aneurysms: A Single-Center Cohort Study

novel p2y12 antagonist

Our preliminary data suggest that morphine may have no impact on mortality in STEMI patients treated with primary PCI and medical therapy according to the current guidelines including novel P2Y12 antagonists.

Impact of morphine use on mortality in STEMI patients treated with primary PCI - preliminary data from a new registry

More novel p2y12 antagonist sentences More Sentences

Learn more from Novel P2y12

More Novel P2y12 sentence examples
10.1097/FJC.0000000000000995

This meta-analysis investigated whether ticagrelor, a novel P2Y12 inhibitor, was superior to clopidogrel and prasugrel in efficacy and safety for DM patients undergoing PCI.

Efficacy and Safety of Ticagrelor in Diabetes Patients Undergoing Percutaneous Coronary Intervention: A Meta-analysis of Randomized Controlled Trials.

More Novel P2y12 sentence examples
10.1055/s-0040-1721773

Therefore, the PD interaction liability of the novel P2Y12 receptor antagonist selatogrel with irreversible (i.

Insights from In Vitro and Clinical Data to Guide Transition from the Novel P2Y12 Antagonist Selatogrel to Clopidogrel, Prasugrel, and Ticagrelor.

More Novel P2y12 sentence examples
10.1093/ehjcvp/pvab035

For over a decade novel P2Y12 inhibitors, which have increased specificity, potency and efficacy have been available, prompting studies which have tested whether these newer agents can be used in aspirin-free anti-platelet regimens to augment clinical benefits in patients post-PCI.

Aspirin-free antiplatelet regimens after PCI: insights from the GLOBAL LEADERS trial and beyond.

More Novel P2y12 sentence examples
10.1093/eurheartj/ehab594

Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes.

Erratum to: CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure

More Novel P2y12 sentence examples
10.3174/ajnr.A7216

BACKGROUND AND PURPOSE: Ticagrelor is a novel P2Y12 antagonist, and little is known about its efficacy and safety in the endovascular treatment of aneurysms.

Ticagrelor versus Clopidogrel in the Dual Antiplatelet Regimen for Intracranial Stenting or Flow-Diverter Treatment for Unruptured Cerebral Aneurysms: A Single-Center Cohort Study

More Novel P2y12 sentence examples
10.1093/EURJPC/ZWAB061.090

Our preliminary data suggest that morphine may have no impact on mortality in STEMI patients treated with primary PCI and medical therapy according to the current guidelines including novel P2Y12 antagonists.

Impact of morphine use on mortality in STEMI patients treated with primary PCI - preliminary data from a new registry

More Novel P2y12 sentence examples
10.1177/1074248418823724

In patients with an acute coronary syndrome undergoing percutaneous coronary intervention, novel P2Y12 receptor inhibitors, prasugrel and ticagrelor, are proposed as “first-line” antiplatelet agents in the absence of contraindications and up to a year from the index event.

De-Escalation of Treatment With Oral P2Y12 Receptor Inhibitors: Current Status and Perspectives

More Novel P2y12 sentence examples
10.1007/s11239-019-01926-6

Prasugrel, a novel P2Y12 receptor antagonist, has been shown to be more effective than clopidogrel for preventing cardiovascular events in patients with acute coronary syndromes undergoing percutaneous coronary intervention.

Pharmacodynamic assessment of prasugrel and clopidogrel in patients with non-cardioembolic stroke: a multicenter, randomized, active-control clinical trial

More Novel P2y12 sentence examples
10.1016/J.EJIM.2018.12.004

We aimed to investigate the therapeutic strategies, the use of novel P2Y12 inhibitors, and the prognostic implication of anemia in a "real world" cohort of ACS patients.

Impact of anemia as risk factor for major bleeding and mortality in patients with acute coronary syndrome.

More Novel P2y12 sentence examples
10.1093/eurheartj/ehz807

Aims To study the pharmacodynamics and pharmacokinetics of selatogrel, a novel P2Y12 receptor antagonist for subcutaneous administration, in patients with chronic coronary syndromes (CCS).

Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes

More Novel P2y12 sentence examples
10.1002/jcph.1318

We aimed to investigate differences in prognosis of acute coronary syndrome patients with and without CKD, focusing on the use of novel P2Y12 receptor inhibitors.

Chronic Kidney Disease and Third‐Generation P2Y12 Inhibitors Use in Patients With Acute Coronary Syndrome: Impact on the Prognosis at 1 Year

More Novel P2y12 sentence examples
10.1080/14656566.2019.1615329

3 h) and was not mitigated by the novel P2Y12 inhibitors.

Bivalirudin infusion in patients with acute coronary syndrome after stenting

More Novel P2y12 sentence examples
10.1093/ehjcvp/pvy030

We studied PPI prescription in ACS patients in the era of novel P2Y12 inhibitors and assessed the association between PPI use and clinical outcomes.

Trends in cardiovascular and bleeding outcomes in acute coronary syndrome patients treated with or without proton-pump inhibitors during the introduction of novel P2Y12 inhibitors: a five-year experience from a single-centre observational registry.

Learn more from Novel P2y12

Keywords related to Novel

Novel P2y12
Encyclopedia

What is/are Novel P2y12?

Novel P2y12 - This meta-analysis investigated whether ticagrelor, a novel P2Y12 inhibitor, was superior to clopidogrel and prasugrel in efficacy and safety for DM patients undergoing PCI. [1] Therefore, the PD interaction liability of the novel P2Y12 receptor antagonist selatogrel with irreversible (i. [2] For over a decade novel P2Y12 inhibitors, which have increased specificity, potency and efficacy have been available, prompting studies which have tested whether these newer agents can be used in aspirin-free anti-platelet regimens to augment clinical benefits in patients post-PCI. [3] Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. [4] BACKGROUND AND PURPOSE: Ticagrelor is a novel P2Y12 antagonist, and little is known about its efficacy and safety in the endovascular treatment of aneurysms. [5] Our preliminary data suggest that morphine may have no impact on mortality in STEMI patients treated with primary PCI and medical therapy according to the current guidelines including novel P2Y12 antagonists. [6] In patients with an acute coronary syndrome undergoing percutaneous coronary intervention, novel P2Y12 receptor inhibitors, prasugrel and ticagrelor, are proposed as “first-line” antiplatelet agents in the absence of contraindications and up to a year from the index event. [7] Prasugrel, a novel P2Y12 receptor antagonist, has been shown to be more effective than clopidogrel for preventing cardiovascular events in patients with acute coronary syndromes undergoing percutaneous coronary intervention. [8] We aimed to investigate the therapeutic strategies, the use of novel P2Y12 inhibitors, and the prognostic implication of anemia in a "real world" cohort of ACS patients. [9] Aims To study the pharmacodynamics and pharmacokinetics of selatogrel, a novel P2Y12 receptor antagonist for subcutaneous administration, in patients with chronic coronary syndromes (CCS). [10] We aimed to investigate differences in prognosis of acute coronary syndrome patients with and without CKD, focusing on the use of novel P2Y12 receptor inhibitors. [11] 3 h) and was not mitigated by the novel P2Y12 inhibitors. [12] We studied PPI prescription in ACS patients in the era of novel P2Y12 inhibitors and assessed the association between PPI use and clinical outcomes. [13]

novel p2y12 receptor

Therefore, the PD interaction liability of the novel P2Y12 receptor antagonist selatogrel with irreversible (i. [1] Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. [2] In patients with an acute coronary syndrome undergoing percutaneous coronary intervention, novel P2Y12 receptor inhibitors, prasugrel and ticagrelor, are proposed as “first-line” antiplatelet agents in the absence of contraindications and up to a year from the index event. [3] Prasugrel, a novel P2Y12 receptor antagonist, has been shown to be more effective than clopidogrel for preventing cardiovascular events in patients with acute coronary syndromes undergoing percutaneous coronary intervention. [4] Aims To study the pharmacodynamics and pharmacokinetics of selatogrel, a novel P2Y12 receptor antagonist for subcutaneous administration, in patients with chronic coronary syndromes (CCS). [5] We aimed to investigate differences in prognosis of acute coronary syndrome patients with and without CKD, focusing on the use of novel P2Y12 receptor inhibitors. [6]

novel p2y12 inhibitor

This meta-analysis investigated whether ticagrelor, a novel P2Y12 inhibitor, was superior to clopidogrel and prasugrel in efficacy and safety for DM patients undergoing PCI. [1] For over a decade novel P2Y12 inhibitors, which have increased specificity, potency and efficacy have been available, prompting studies which have tested whether these newer agents can be used in aspirin-free anti-platelet regimens to augment clinical benefits in patients post-PCI. [2] We aimed to investigate the therapeutic strategies, the use of novel P2Y12 inhibitors, and the prognostic implication of anemia in a "real world" cohort of ACS patients. [3] 3 h) and was not mitigated by the novel P2Y12 inhibitors. [4] We studied PPI prescription in ACS patients in the era of novel P2Y12 inhibitors and assessed the association between PPI use and clinical outcomes. [5]

novel p2y12 antagonist

BACKGROUND AND PURPOSE: Ticagrelor is a novel P2Y12 antagonist, and little is known about its efficacy and safety in the endovascular treatment of aneurysms. [1] Our preliminary data suggest that morphine may have no impact on mortality in STEMI patients treated with primary PCI and medical therapy according to the current guidelines including novel P2Y12 antagonists. [2]